Collaboration with Public Health England established to understand activity of GS-13 against antibacterial-resistant pathogens

GS-13 is our fatty acid formulation in development as a solution to systemic and antibiotic-resistant infections.

Wintermute Biomedical
August 12, 2022

We are excited to announce we are collaborating with Mark Sutton and Charlie Hind at Public Health England (PHE) to understand the mechanism of action of GS-13 against antibiotic-resistant infections.

The overuse of antimicrobials in medicine, agriculture, and the environment has caused many infectious pathogens – particularly bacteria and fungi – to develop mechanisms of resistance against the antibiotics we have relied on since their discovery. This phenomenon is referred to as antimicrobial resistance (AMR).

A growing number of pathogens are becoming resistant to these antimicrobials, meaning there is a risk that the therapies we currently take for everyday infections may be rendered ineffective.

The severity of AMR is acknowledged by the world’s leading health bodies; the World Health Organization states that AMR is one of the greatest public health threats currently facing humanity.  

Wintermute Biomedical was created to find alternatives to antibiotics that could help curb the effects of antimicrobial resistance. We want to work with the best labs in the world to make this happen, so we contacted PHE to set up a collaboration to understand GS-13’s activity and suitability as a systemic antibiotic.

With the development of antimicrobial resistance, these infections are extremely difficult to treat. GS-13 could be a much-needed alternative to antibiotics to treat patients with these infections.

We look forward to the results of this collaboration.